



ASX ANNOUNCEMENT

Retirement of Martin Rogers as Chairman of Actinogen Medical

Sydney, 30 November 2016: Actinogen Medical Limited (ASX: ACW) today confirmed the retirement of Chairman Martin Rogers. As previously announced, Mr Rogers proposed to step down as Chairman of Actinogen Medical at the conclusion of the AGM today. Today, Mr Rogers also resigns as a Director of Actinogen Medical.

Mr Rogers has been Chairman since Actinogen Medical's inception in late 2014. He championed the initial establishment of the business, including the recruitment of Dr Bill Ketelbey as CEO and Vincent Ruffles as VP Clinical Research and his broad biotech experience and immense network and capital market expertise came to the fore with Actinogen's very successful capital raising in May 2015. He leaves Actinogen Medical in great shape, with the business poised to start patient recruitment into XanADu, their Phase II clinical trial of Xanamem in mild Alzheimer's disease. XanADu will be the largest Alzheimer's clinical trial run by an Australian biotech company, globally.

Actinogen Medical thanks Mr Rogers for his valued input to, and guidance of the business over the last 2 years, and particularly during the early months leading up to the capital raise. The business and the Board wish Mr Rogers all the very best in his new endeavours.

Until such time as a replacement Chairman is recruited, Dr Jason Loveridge will function as interim Chairman. His appointment takes effect from today.

ENDS

Actinogen Medical

Dr Bill Ketelbey

CEO & Managing Director

P: +61 2 8964 7401

E: bill.ketelbey@actinogen.com.au

 @BillKetelbey

About Actinogen Medical

Actinogen Medical (ASX: ACW) is an ASX-listed biotech company focused on innovative approaches to treating cognitive decline that occurs in chronic neurodegenerative and metabolic diseases. Xanamem™, Actinogen's lead candidate drug, blocks excess production of the stress hormone cortisol in the brain. There is growing evidence that chronic stress and excess cortisol leads to changes in the brain affecting memory, and to the development of amyloid plaques and neural death – all hallmarks of Alzheimer's disease. In 2016, the Company initiated XanADu, a Phase II efficacy and safety trial of Xanamem™ in mild Alzheimer's disease.

ACTINOGEN MEDICAL LIMITED TRADING AS ACTINOGEN MEDICAL ACN 086 778 476 ASX | ACW

Level 9, Suite 1, 68 Pitt Street, Sydney NSW 2000 AUSTRALIA

TELEPHONE +61 2 8964 7401

WEB www.actinogen.com.au

About Xanamem™

Xanamem™ is being developed as a promising new therapy for Alzheimer's disease, a condition with a multibillion dollar market potential. In the US alone, the cost of managing Alzheimer's disease in 2013 was estimated to be US\$250bn, and is set to increase to US\$1 trillion by 2050, outstripping the treatment costs of all other diseases. Alzheimer's disease is now the second leading cause of death in Australia, behind ischaemic heart disease. Xanamem™'s novel mechanism of action sets it apart from other Alzheimer's treatments. It works by blocking the excess production of cortisol - the stress hormone - in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer's disease.